Cologuard Plus
Exact Sciences Corporation · Decision date Mar 13, 2026
What did the FDA decide?
FDA records P230043/S005 as a supplement to PMA P230043, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 13, 2026.
FDA approval order statement
a manufacturing process change and use of an alternative sub-component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Mar 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230043/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Exact Sciences Corporation
- Product code
- PHP
- Decision code
- OK30
- Decision date
- Mar 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.
- Applicant
- Exact Sciences Corporation
- Product code
- PHP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230043/S001 · Related supplement
Cologuard Plus
P230043/S002 · Related supplement
Cologuard Plus
P230043/S003 · Related supplement
Stool DNA (sDNA) Test, Cologuard Plus
P230043/S005 received
Application receipt date recorded by FDA.
P230043/S004 · Related supplement
Cologuard Plus
P230043/S005 · FDA decision
30-Day Notice
P230043/S008 · Related supplement
Cologuard Plus
P230043/S006 · Related supplement
Cologuard Plus
P230043/S007 · Related supplement
Cologuard Plus
P230043/S009 · Related supplement
Cologuard Plus
P230043/S010 · Related supplement
Cologuard Plus
Timeline entries are records held by MedtechLedger for P230043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cologuard PlusP230043/S001 | Exact Sciences Corporation | PMA supplement | Jul 18, 2025 | FDA |
Cologuard PlusP230043/S002 | Exact Sciences Corporation | PMA supplement | Jul 24, 2025 | FDA |
Stool DNA (sDNA) Test, Cologuard PlusP230043/S003 | Exact Sciences Corporation | PMA supplement | Jan 6, 2026 | FDA |
Cologuard PlusP230043/S004 | Exact Sciences Corporation | PMA supplement | Feb 9, 2026 | FDA |
Cologuard PlusP230043/S008 | Exact Sciences Corporation | PMA supplement | Apr 22, 2026 | FDA |
Cologuard PlusP230043/S006 | Exact Sciences Corporation | PMA supplement | May 27, 2026 | FDA |
Cologuard PlusP230043/S007 | Exact Sciences Corporation | PMA supplement | Jun 2, 2026 | FDA |
Cologuard PlusP230043/S009 | Exact Sciences Corporation | PMA supplement | Jun 9, 2026 | FDA |
Cologuard PlusP230043/S010 | Exact Sciences Corporation | PMA supplement | Aug 3, 2026 | FDA |
Explore the linked device profile
Other records with product code PHP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SimpleScreen CRCP250029/S003 | Freenome, LLC | PMA supplement | Oct 27, 2026 | FDA |
ShieldP230009/S021 | Guardant Health, Inc. | PMA supplement | Oct 5, 2026 | FDA |
ShieldP230009/S020 | Guardant Health, Inc. | PMA supplement | Sep 16, 2026 | FDA |
SimpleScreen CRCP250029/S001 | Freenome, LLC | PMA supplement | Aug 26, 2026 | FDA |
SimpleScreen CRCP250029 | Freenome, LLC | PMA approval | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Exact Sciences Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5505 Endeavor Ln., Madision, WI, 53719
Sources and methodology
- Original FDA record: P230043/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






